@entity454 ( @entity454 ) presents a complex syndrome in which inflammatory and metabolic processes contribute to disease progression and development of comorbid conditions. Over  1 trillion is spent globally on @entity454 care. Plasma samples collected from 83 @entity454 @entity1 prior to hemodialysis were profiled for metabolic and inflammatory biomarker concentrations. Concentrations were compared between groups with and without history of @entity64 , @entity1187 ( @entity1187 ), @entity712 ( @entity712 ), and @entity453 ( @entity453 ). The 25 @entity1 (30.1%) with history of @entity64 demonstrated decreased plasma interferon-y levels (p   =   0.042) and elevated plasma resistin, @entity1192 , and leptin levels (p   =   0.008, 0.021, 0.026, respectively) when compared with @entity454 @entity1 without history of @entity64 . The 14 @entity1 (16.9%) with history of @entity1187 demonstrated elevated plasma @entity650 levels (p   =   0.040) when compared with @entity454 @entity1 without history of @entity1187 . The 30 @entity1 (36.1%) with history of @entity712 demonstrated decreased plasma leptin levels (p   =   0.031) and elevated plasma @entity1356 levels (p   =   0.042) when compared with @entity454 @entity1 without history of @entity712 . Finally, the 39 @entity1 (47.0%) with history of @entity453 demonstrated elevated plasma @entity1192 levels (p   =   0.049) when compared with @entity454 @entity1 without history of @entity453 . Plasma biomarker concentration disturbances were observed in @entity454 @entity1 with history of @entity64 , @entity1187 , @entity712 , and @entity453 when compared with @entity454 @entity1 without such history. Proinflammatory biomarker elevations were seen in @entity64 , @entity1187 , @entity712 and @entity453 , while adipocytokine aberrations were observed in both @entity64 and @entity712 . These studies demonstrate that biomarker profiling of vascular comorbidities in @entity454 may provide useful diagnostic and prognostic information in the management of @entity454 @entity1 .

Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'CHF'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b'] @entity1192 :: ('3552', 'Gene') :: ['IL-1a', 'interleukin (IL)-1a'] @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease'] @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD', 'End-stage renal disease']
@entity454 :: (MESH:D007676,Disease) :: ['End-stage Renal Disease']
